RAB13

Across TCGA pan-cancer cohorts, RAB13 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAB13 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher RAB13 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAB13 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, BRCA, and UCEC are the cancer types where RAB13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.177	0.796	<.001	14	view →
BRCA	OS	Median	All	0.107	0.578	.004	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.444	.033	10	view →
SKCM	DFS	Median	All	0.354	0.615	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RAB13–LUSC (DFS)

Open the LUSC breakdown →